Literature DB >> 6779261

Cost-effectiveness of a shared-management delivery system for the care of children with cancer.

F Strayer, C T Kisker, C Fethke.   

Abstract

Costs of two alternative methods for obtaining comparable quality outpatient care for pediatric cancer patients were examined. Costs incurred in obtaining care from specialists, "specialist-management," were compared to costs incurred in obtaining "shared-management," care provided by specialists and primary physicians combined. Shared-management medical costs for outpatient care were 10% less than they would have been had the care been obtained from specialists. The nonmedical costs of transportation, parking, food away from home, and lost productivity or income were all less under the shared-management medical care delivery system than they would have been had specialist management been utilized. The total estimated cost differences between the alternative systems for the delivery of outpatient care ($2,191.34) represents for shared management a mean saving per patient of approximately 29% in direct out-of-pocket expenses and a 59% savings in the indirect costs of lost income or productivity. A total theoretical mean 41% saving per patient was shown to accrue through the use of shared management.

Entities:  

Mesh:

Year:  1980        PMID: 6779261

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  3 in total

1.  Relative costs of specialist services in a family practice population.

Authors:  P G Norton; W Nelson; H L Rudner; E V Dunn
Journal:  CMAJ       Date:  1985-10-15       Impact factor: 8.262

2.  Systematic review of cancer treatment programmes in remote and rural areas.

Authors:  N C Campbell; L D Ritchie; J Cassidy; J Little
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

3.  Follow-up of breast cancer in primary care vs specialist care: results of an economic evaluation.

Authors:  E Grunfeld; A Gray; D Mant; P Yudkin; R Adewuyi-Dalton; D Coyle; D Cole; J Stewart; R Fitzpatrick; M Vessey
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.